Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
临床1期微生物疗法引进/卖出
Dive Brief:
Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it struggles to fund operations.
Under a nonbinding memorandum of understanding announced Thursday, the Swiss company will acquire all the product and intellectual property rights to Vowst, which was approved in the U.S. in 2023 to prevent the recurrence of difficult-to-treat C. diff infections. Seres expects the transaction to close within 90 days.
The company didn’t disclose exact financial terms for the deal, saying only that it would receive capital infusions including an upfront payment. Seres said it will use the money to retire an existing debt facility with Oaktree Capital Management and extend its cash runway into the fourth quarter of 2025.
Dive Insight:
The sale will allow Seres to focus on advancing SER-155 and other experimental microbiome therapies designed to fight infections. In April, the company announced it had completed patient enrollment for a Phase 1b trial of SER-155 in patients who received allogeneic hematopoietic stem cell transplants.
Seres has been working with Nestlé since 2016 when the companies signed a development and commercialization deal involving four medicines. In 2021, Nestlé agreed to pay Seres to expand the collaboration and acquire more commercialization rights to one of those drugs, SER-109, now sold under the brand name Vowst.
The pill is made from human fecal matter that’s been screened and purified. It’s designed to repopulate the gut with helpful bacteria to ward off infections. It was the second microbiota therapy to win Food and Drug Administration approval and the first one cleared for oral administration. But a year after the launch of Vowst, Seres is struggling. The company posted a net loss of $40.1 million in the first quarter and told investors in May that its cash was sufficient to carry operations only into the fourth quarter of this year. That was even after eliminating 41% of its workforce in a restructuring announced in November.
'
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。